Mutant K-ras2 in serum

Andreyev, H. J. N.; Benamouzig, R.; Beranek, M.; Clarke, P.; Cunningham, D.; Norman, A. R.; Giaretti, W.; de Goeij, A. F. P. M.; Iacopetta, B. J.; Jullian, E.; Krtolica, K.; Lee, J. Q.; Wang, S. T.; Lees, N.; Al-Mulla, F.; Muller, O.; Pauly, M.; Pricolo, V.; Russo, A.; Troungos, C.
June 2003
Gut;Jun2003, Vol. 52 Issue 6, p915
Academic Journal
No abstract available.


Related Articles

  • A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up. Ryan, B.M.; Lefort, F.; McManus, R.; Daly, J.; Keeling, P.W.N.; Weir, D.G.; Kelleher, D. // Gut;Jan2003, Vol. 52 Issue 1, p101 

    Background and aims: Mutant tumour derived DNA has been detected in the sera of colorectal cancer patients. We investigated if mutant serum KRAS2 was detectable preoperatively in a large group of patients with colorectal neoplasia. A prospective study of 94 patients who underwent putative...

  • K-Ras4B phosphorylation at Ser181 is inhibited by calmodulin and modulates K-Ras activity and function. Alvarez-Moya, B; López-Alcalá, C; Drosten, M; Bachs, O; Agell, N // Oncogene;11/4/2010, Vol. 29 Issue 44, p5911 

    Fine tuning of Ras activity is widely known as a mechanism to induce different cellular responses. Recently, we have shown that calmodulin (CaM) binds to K-Ras and that K-Ras phosphorylation inhibits its interaction with CaM. In this study we report that CaM inhibits K-Ras phosphorylation at...

  • A rat virus visits the clinic: translating basic discoveries into clinical medicine in the 21st century. Boland, C.R.; Goel, A. // Gut;Jan2003, Vol. 52 Issue 1, p8 

    Reports on the presence of mutant forms of the KRAS2 gene in the serum of patients who have undergone putatively curative surgery for colorectal cancer. Use of information to predict tumor recurrences and to guide novel therapies in the future by identifying individuals at greatest risk of...

  • Cancer: A tumour's Kras behaviour.  // Nature;5/3/2012, Vol. 485 Issue 7396, p8 

    The article focuses on a study by Alec Kimmelman and colleagues related to cancer, which revealed that pancreatic tumours need mutant Kras to survive.

  • Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab. Garcia-Albeniz, Xabier; Pericay, Carles; Alonso-Espinaco, Virginia; Alonso, Vicente; Escudero, Pilar; Fern�ndez-Martos, Carlos; Gallego, Rosa; Gasc�n, Pere; Castellv�-Bel, Sergi; Maurel, Joan // Tumor Biology;2011, Vol. 32 Issue 2, p417 

    The purpose of the study was to prospectively explore the role of serum MMP-7 as a predictive and prognostic marker of anti-epidermal growth factor receptor (EGFR) therapy and irinotecan efficacy in third-line advanced colorectal cancer therapy. One hundred patients were recruited prospectively...

  • KRAS mutant allele-specific imbalance in lung adenocarcinoma. Chiosea, Simion I; Sherer, Carol K; Jelic, Tomislav; Dacic, Sanja // Modern Pathology;Dec2011, Vol. 24 Issue 12, p1571 

    The significance of KRAS mutant allele-specific imbalance (MASI) in lung adenocarcinomas is unknown. KRAS MASI was defined as predominance of the mutant allele over the wild-type allele. We assessed the frequency of KRAS MASI by comparing peak heights of mutant and wild-type alleles on...

  • Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome. Ihle, Nathan T.; Byers, Lauren A.; Kim, Edward S.; Saintigny, Pierre; Lee, J. Jack; Blumenschein, George R.; Tsao, Anne; Liu, Suyu; Larsen, Jill E.; Wang, Jing; Diao, Lixia; Coombes, Kevin R.; Chen, Lu; Zhang, Shuxing; Abdelmelek, Mena F.; Tang, Ximing; Papadimitrakopoulou, Vassiliki; Minna, John D.; Lippman, Scott M.; Hong, Waun K. // JNCI: Journal of the National Cancer Institute;Feb2012, Vol. 104 Issue 3, p228 

    Background Mutations in the v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) play a critical role in cancer cell growth and resistance to therapy. Most mutations occur at codons 12 and 13. In colorectal cancer, the presence of any mutant KRas amino acid substitution is a negative...

  • Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer. Sunaga, N; Kaira, K; Imai, H; Shimizu, K; Nakano, T; Shames, D S; Girard, L; Soh, J; Sato, M; Iwasaki, Y; Ishizuka, T; Gazdar, A F; Minna, J D; Mori, M // Oncogene;8/22/2013, Vol. 32 Issue 34, p4034 

    KRAS mutations are one of the most common driver mutations in non-small-cell lung cancer (NSCLC) and finding druggable target molecules to inhibit oncogenic KRAS signaling is a significant challenge in NSCLC therapy. We recently identified epiregulin (EREG) as one of several putative...

  • Cten Is Targeted by Kras Signalling to Regulate Cell Motility in the Colon and Pancreas. Al-Ghamdi, Saleh; Albasri, Abdulkader; Cachat, Julien; Ibrahem, Salih; Muhammad, Belal A.; Jackson, Darryl; Nateri, Abdolrahman S.; Kindle, Karin B.; Ilyas, Mohammad // PLoS ONE;2011, Vol. 6 Issue 6, p1 

    CTEN/TNS4 is an oncogene in colorectal cancer (CRC) which enhances cell motility although the mechanism of Cten regulation is unknown. We found an association between high Cten expression and KRAS/BRAF mutation in a series of CRC cell lines (p = 0.03) and hypothesised that Kras may regulate...

  • Contribution of enhanced transcriptional activation by ER to [12Val] K-Ras mediated NIH3T3 cell transformation. Kato, Kiyoko; Ueoka, Yousuke; Kato, Keiji; Hachiya, Toshiro; Nishida, Jun-ichi; Wake, Norio // Oncogene;12/18/97, Vol. 15 Issue 25, p3037 

    We investigated the biological significance of estrogen receptors (ER) in NIH3T3 cell transformation by the [12Val] K-Ras mutant. This mutant enhanced the steady state level of ER. Cells expressing mutant K-Ras (K12V cell) were tumorigenic. To determine the role of ER accumulation in...


Read the Article


Sign out of this library

Other Topics